Investors > News Releases
Jun 05, 2019
Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference
Corporate
Jun 03, 2019
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
Products
Jun 02, 2019
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
Pipeline
May 14, 2019
Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
Products
May 09, 2019
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy
Pipeline
May 07, 2019
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
Financial
May 01, 2019
Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®
Pipeline
May 01, 2019
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
Financial
Apr 30, 2019
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer
Products
Apr 23, 2019
Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019
Financial
Apr 23, 2019
Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting
Products
Apr 17, 2019
Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List
Corporate
Apr 09, 2019
Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test
Pipeline
Apr 04, 2019
Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership
Pipeline
Apr 02, 2019
Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests
Products